



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

REGD.OFFICE- PLOT NOS. 25,26,29 &amp; 30, PILERNE INDUSTRIAL ESTATE,

MARRA, SALIGAO, BARDEZ GOA- 403 511.

## STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31/12/2015

## PART I

(in Lacs)

Particulars	3 months ended 31/12/2015	Preceding 3 months ended 30/09/2015	Corresponding 3 months ended the previous year 31/12/2014	Year to date figures for current period ended 31/12/2015	Year to date figures for previous period ended 31/12/2014	Previous year ended 31/03/2015
(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income from continuing operations						
(a) Net sales/income from operations (Net of excise duty)	1,179.21	1,171.93	1,142.56	3,342.71	3,158.74	4,440.30
Less: Trade Discount	124.25	125.61	126.03	357.85	339.35	480.14
(b) Other operating income	1,054.96	1,046.32	1,016.53	2,984.86	2,819.39	3,960.16
<b>Total income from operations (net)</b>	<b>1,054.96</b>	<b>1,046.32</b>	<b>1,016.53</b>	<b>2,984.86</b>	<b>2,819.39</b>	<b>3,960.16</b>
2 Expenses						
(a) Cost of materials consumed	250.79	252.83	158.36	625.40	400.35	676.18
(b) Purchases of traded goods	24.73	518.27	457.69	1,057.39	1,061.39	1,382.38
(c) Changes in inventories of finished goods, work-in-progress, traded goods & Stock in Transit	298.51	(182.16)	(55.54)	(71.43)	108.14	143.87
(d) Employee benefits expense	107.70	97.39	93.43	309.73	271.82	368.99
(e) Depreciation and amortisation expense	11.73	11.66	15.87	36.71	46.86	57.46
(f) Other expenses	288.84	304.03	286.81	862.71	775.81	1,145.08
<b>Total expenses</b>	<b>982.29</b>	<b>1,002.02</b>	<b>956.62</b>	<b>2,820.51</b>	<b>2,664.37</b>	<b>3,773.96</b>
3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	72.66	44.30	59.90	164.35	155.02	186.20
4 Other income	0.71	2.80	3.62	6.97	7.91	13.69
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	73.37	47.10	63.52	171.31	162.94	199.89
6 Finance costs	45.12	42.84	32.20	122.04	103.13	137.02
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	28.25	4.26	31.31	49.27	59.81	62.87
8 Exceptional items	-	0.00	-	-	-	-
9 Profit / (Loss) from ordinary activities before tax (7 + 8)	28.25	4.26	31.31	49.27	59.80	62.87
10 Tax expense	6.48	3.26	7.34	13.36	13.51	21.51
11 Net Profit / (Loss) from ordinary activities after tax (9 + 10)	21.76	1.00	23.97	35.91	46.29	41.36
12 Extraordinary items (net of tax expense)	0.00	0.00	0.00	0.00	-	-
13 Net Profit / (Loss) for the period (11 + 12)	21.76	1.00	23.97	35.91	46.29	41.36
14 Share of profit / (loss) of associates*	0.00	0.00	0.00	0.00	-	0.00
15 Minority interest *	-	-	-	-	-	-
16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	21.76	1.00	23.97	35.91	46.29	41.36
17 Paid-up equity share capital (Face Value of the Share shall be indicated)	708.10	708.10	708.10	708.10	708.10	708.10
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						
9.i Earnings per share (before extraordinary items) (of 10/- each) (not annualised):	0.31	0.01	0.34	0.51	0.65	0.58
(a) Basic						
(b) Diluted						
9.ii Earnings per share (after extraordinary items) (of 10/- each) (not annualised):						
(a) Basic						
(b) Diluted						

Note:

- The Company operates in a single business segment namely "Pharmaceuticals Products"
- The above Unaudited results have been reviewed by the Audit Committee Meeting on Saturday, 13th February 2016 and approved by the Board of Directors at its Meeting held on Saturday, 13th February 2016.

PLACE: MUMBAI  
DATE: 13th February, 2016



For SANDU PHARMACEUTICALS LIMITED

UMESH B. SANDU  
MANAGING DIRECTOR  
DIN:- 01132141

### **Limited Review Report**

We have reviewed the accompanying statement of unaudited financial results of **SANDU PHARMACEUTICALS LIMITED** for the period ended 31/12/2015. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For Joshi Joshi & Co.  
Chartered Accountants  
(FRN: 104393w)

A handwritten signature in black ink, appearing to be "M. M. Joshi".

(M. M. Joshi)  
Proprietor  
M.No-42466 of 89

Mumbai

Date: 13/02/2016